Thrombocytopenia differential diagnosis: Difference between revisions
No edit summary |
|||
Line 10: | Line 10: | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="5" |Category | |||
! colspan="2" rowspan="5" |Condition | ! colspan="2" rowspan="5" |Condition | ||
! rowspan="5" |Mechanism | ! rowspan="5" |Mechanism | ||
Line 31: | Line 32: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | |||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
Line 47: | Line 49: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!Decreased platelet production | |||
!Platelet destruction in bloodstream | !Platelet destruction in bloodstream | ||
!Platelet destruction in spleen/liver | !Platelet destruction in spleen/liver | ||
Line 53: | Line 56: | ||
!WBC | !WBC | ||
|- | |- | ||
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematology | |||
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders | ! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders | ||
! align="center" style="background:#DCDCDC;" + |Myelodysplastic syndromes | ! align="center" style="background:#DCDCDC;" + |Myelodysplastic syndromes | ||
Line 509: | Line 513: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!Category | |||
! colspan="2" |Condition | ! colspan="2" |Condition | ||
!Mechanism | !Mechanism | ||
Line 539: | Line 544: | ||
!Associated findings | !Associated findings | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders | |||
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction | | align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction | ||
Line 659: | Line 665: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection-induced | |||
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections | ! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections | ||
! align="center" style="background:#DCDCDC;" + |Sepsis | ! align="center" style="background:#DCDCDC;" + |Sepsis | ||
Line 771: | Line 778: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 781: | Line 784: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | ! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 812: | Line 819: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ||
Line 876: | Line 883: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!Category | |||
! colspan="2" |Condition | ! colspan="2" |Condition | ||
!Mechanism | !Mechanism | ||
Line 906: | Line 914: | ||
!Associated findings | !Associated findings | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + | | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medication/toxicity | ||
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | |||
! align="left" style="background:#DCDCDC;" + | | ! align="left" style="background:#DCDCDC;" + | | ||
* Antibiotics | |||
** Sulfonamides | |||
** Ampicillin | |||
** Piperacillin | |||
** Vancomycin | |||
** Rifampin | |||
* Older antiepileptic agents | |||
** carbamazepine | |||
** Phenytoin | |||
* Quinine | * Quinine | ||
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies | | align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
Line 939: | Line 953: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
Line 951: | Line 965: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 970: | Line 981: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ||
Line 1,063: | Line 1,077: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI | |||
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease | ! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,124: | Line 1,139: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!Category | |||
! colspan="2" |Condition | ! colspan="2" |Condition | ||
!Mechanism | !Mechanism | ||
Line 1,154: | Line 1,170: | ||
!Associated findings | !Associated findings | ||
|- | |- | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular | |||
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma | ||
| align="center" style="background:#F5F5F5;" + |Platelet destruction | | align="center" style="background:#F5F5F5;" + |Platelet destruction | ||
Line 1,244: | Line 1,261: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | |||
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol | ! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 15:34, 15 August 2018
Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytopenia differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis |
Risk calculators and risk factors for Thrombocytopenia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.
Overview
Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | |||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | BT | UA | ||||||||||||||||
Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Plt | HB | WBC | |||||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | |||||||||||||||||||||||||||
Aplastic anemia | + | |||||||||||||||||||||||||||||
Acute leukemia | + | |||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | |||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | ||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | |||||||||||||||||||||||||||||
DIC | + | |||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | + | ||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | + | |||||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | + | |||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | Autoantibody-mediated syndrome | + | ||||||||||||||||||||||||||||
Felty's syndrome | Splenomegaly | + | ||||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | ↑ | ↑ | |||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | ||||||||||||||||||||||||||||
Tick-borne infection | + | |||||||||||||||||||||||||||||
Viral infections | HIV |
|
+ | + | + | |||||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | |||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Medication/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | + | + | |||||||||||||||||||||||||
Heparin-induced thrombocytopenia | + | |||||||||||||||||||||||||||||
Cytotoxic chemotherapy | + | |||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | ||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
GI | Chronic liver disease | + | ||||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma | Platelet destruction | + | |||||||||||||||||||||||||||
Aortic aneurysm | Platelet destruction | + | ||||||||||||||||||||||||||||
Cardiopulmonary bypass | Platelet destruction | + | ||||||||||||||||||||||||||||
Other | Alcohol | + | ||||||||||||||||||||||||||||
Post-transfusion purpura | Immune mediated platelet destruction | + | ||||||||||||||||||||||||||||
Gestational thrombocytopenia | ||||||||||||||||||||||||||||||
HELLP syndrome |